Change Agents

Keto Air becomes investable only if CHGA’s effective North American distributor position, simple FDA-registered consumer sales pathway, and targeted social/Law Enforcement Association channels create repeatable demand before ketosis monitoring remains a niche wellness tool. If this holds, Keto Air can fund part of the company’s pivot; if it breaks, the legacy revenue base is too small to support the current valuation or cash burn.

RPM/Avalon Quantum AI will create value only if creators and enterprises treat automated topic discovery, video sourcing, scriptwriting, AI avatars, and three-minute video assembly as a workflow worth paying for rather than a feature bundled by larger platforms. If RPM monetizes, CHGA gains a higher-upside AI revenue leg; if not, the AI acquisition is narrative value without operating leverage.

Going-concern liquidity, not product vision, is the near-term control variable; CHGA must secure external financing or cash proceeds before burn and liabilities force abandonment, asset sales, or deeply dilutive equity. If financing arrives on acceptable terms, holders keep exposure to the Keto Air and RPM options; if not, survival financing can transfer most upside away from current shareholders.

Management’s cash-preservation pivots only improve survival odds if exiting lab services, suspending cellular-therapy R&D, and discontinuing the THC breathalyzer lower overhead faster than Keto Air marketing and RPM integration add new costs. If focus reduces burn, the company buys time for product-market fit; if expenses re-accelerate, even successful product tests may require punishing dilution.